2Liu JS, Kuo SR, Mc Hugh MM, et al. Adozelesin triggers DNA damage response pathways and SV40 DNA replication through replication protein A inactivation [J ]. J Biol Chem, 2000,275 (2) : 1391-1397.
3Awada A, Punt CJ, Piccart MJ , et al. Phase I study of Carzelesin(U-80,244) given (4-weekly) by intravenous bolus schedule [J]. Br J Cancer, 1999,79 (9-10):1454-1461.
4Armand JP, Seymour L, Evans TR. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines, preliminary results of phase I clinical trials[J] .Eur J Cancer,1999,35 Suppl 1:S14-18.
5Igarashi H, Ito T, Ogoshi K, et al. Successful arterial administration therapy of SMANCS for liver metastasis of malignant insulinoma[ J]. Pancreas, 1999, 19 (2): 207-210.
6Van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometeial cancer after tomoxifen of breast cancer[J]. Lancet, 1994,343(8895) :448.
7Uchida N, Takeda Y, Kasai H, et al. Antitumor efficacy of nedaplation, a novel platinum complex, with cyclophosphamide in rnurine and human tumor model[ J ].Anticancer Res, 1998,18(5A) :3375-3379.
8Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity [J]. Ann Oncol,2002,13(12) : 1841-1851.
9Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancel[J]. Oncologist, 2002,7(Soppl 5) :29-35.
10Holm-Hansen SV, Kamby C, Dombemowsky P. Herceptin(traszumab) :a new exciting theraprutic principlein breast cancer[J]. Ugeskr Laeger,2000,162(2) : 189-190.
